S-23 vs LGD-4033: Comparing Development and Research
Introduction
S-23 and LGD-4033 are both selective androgen receptor modulators (SARMs), but they have significantly different development histories and clinical progressions.
What Was S-23 Designed To Do?
S-23 was developed in academic research settings, primarily as a potential male contraceptive. It is designed to selectively bind to androgen receptors. In practical terms, this means S-23 aims to target specific tissues, minimizing side effects in non-target areas. However, it remains in the preclinical stage.
What Was LGD-4033 Designed To Do?
LGD-4033 was developed by Ligand Pharmaceuticals to combat muscle wasting and osteoporosis-related conditions. Like S-23, it selectively targets androgen receptors. LGD-4033 has advanced into early-stage human clinical trials, offering preliminary insights into its effectiveness and safety in humans.
Key Differences
| Aspect | S-23 | LGD-4033 |
|---|---|---|
| Developer Origin | Academic Research | Ligand Pharmaceuticals |
| Original Research Focus | Male Contraceptive | Muscle Wasting & Osteoporosis |
| Clinical Progression | Preclinical | Early Human Trials |
| Availability of Human Data | None | Available |
| Intended Therapeutic Direction | Contraceptive Use | Muscle & Bone Related Conditions |
What Actually Separates Them?
The key distinction between S-23 and LGD-4033 is that LGD-4033 has entered human trials, while S-23 has not moved beyond preclinical studies. This is crucial for research evaluation, as human trials provide essential data on safety and efficacy that preclinical studies alone cannot offer.
Legal Considerations + Research Disclaimer
These compounds are currently under research and are not approved for human use outside of clinical trials. The information provided is for educational purposes only. Please consult healthcare professionals before considering any new treatment options.